TheScientist.com - Magazine of the Life Sciences, Every Day, Online
  Please Login or Register
  • Home
  • Community
  • Current Issue
  • Browse Archive
  • Careers
  • Video & Multimedia
  • Subscribe

Front Cover
Advertisement
Front Cover
Supplements
  • Life Sciences in
    the Greater
    Phila. Region
  • Schizophrenia
  • NC: State of the Life Sciences
  • Autoimmunity


Survey Series
  • Best Places to Work
  • $alary $urvey
  • Lab Web Site and
    Video Awards

The Scientist Daily
  • Science headlines delivered daily.
    Register today.

For Advertisers
  • Advertise with Us
  • Contact Ad Team
  • 2009 Media Kit



by SPIS MedWire

RESEARCH ROUND-UP

Lipid profiles and hypertension

Email: SPIS MedWire - medwire@sciencenow.com
News from The Scientist 2000, 1(1):20000817-06

Published 17 August 2000

LONDON, August 17 (SPIS MedWire)There is a disparity between the therapeutic reduction of blood pressure and the consequent risk of myocardial infarction, with the decrease in MI rates being less than expected from the magnitude of the decrease in blood pressure levels. To investigate the role of lipid and hemostatic factors in the pathogenesis of hypertension, Marques-Vidal and multicenter colleagues assessed a sample of men aged 50 to 59 years living in France (n=7,050) and Northern Ireland (n=2,374). After adjustment for potential confounders (age, BMI, education, drug treatment for hyperlipidemia, alcohol and tobacco consumption) untreated hypertensive subjects had significantly higher levels of total cholesterol, triglyceride, apoproteins A-I and B and plasminogen activator inhibitor-1 (PAI-1) activity than normotensive subjects. Analysis of the subjects on monotherapy showed beta-blockers decreased total cholesterol and HDL parameters and ACE inhibitors decreased LDL-related parameters, while no effect was found for the other antihypertensive drugs (thiazide and other diuretics, calcium channel blockers). The results confirm that hypertensive subjects are characterised by an unfavorable lipid and hemostatic profile, and the authors comment that their findings "contribute to the general recognition of the need to screen hypertensive patients for lipid disturbances." The results also indicate that antihypertensive treatment with beta-blockers is associated with lower levels of HDL-related parameters, whereas treatment with ACE inhibitors appears to exert a small beneficial effect on total cholesterol and LDL-related parameters.


Not yet registered? Get free access
 

The article you are attempting to read is Premium content which is only available to our online subscribers.

 
 

Email

Password

> Forgot Password?
> FAQ
> Subscribe

 
Not yet registered? Get free access
 

Subscribing to The Scientist is easy and inexpensive.

 

And you can choose from many options. Try us out with an online day pass starting at only $4.95. Or, get it all with unlimited online access to The Scientist Archive and door-to-door delivery of our monthly print magazine.

 
  Not yet registered? Get free access  
 

The Scientist also offers site licenses to institutions and organizations. When your librarian adds The Scientist to the library's collection, you can get unlimited online access through your place of work or study.
Recommend The Scientist today

 



About TS | Contact | Advertise | Editorial Advisory Board | Privacy Policy
© 1986-2008 The Scientist